MiSight 1 day contact lenses are proven to slow the progression of myopia in ageappropriate children¹ and are child friendly¹

MiSight® 1 day clinical trial — Overall Findings

- Over a 3 year period, MiSight* 1 day slowed the progression of myopia in children aged 8-12 at the initiation of treatment by 59% on average, and 41% of eyes had no progression.*1
- At 6 years, 23% of eyes had no progression*3
- The total progression in axial length with MiSight® 1-day wearers over 6 years matches the progression of the first 2 years in the control group during an important period of eye growth for age-appropriate children*3
- MiSight* 1 day treatment period of 6 years vs. 3 years did not alter the rate of slowing refractive error
- Children wearing MiSight[®] 1 day achieved excellent visual acuity[†] across all visits throughout 6 years of clinical study^{1,3}
- Children can successfully wear MiSight* 1 day contact lenses with minimal impact on ocular physiology*1,3,5

*Compared to single vision lens, -0.25D or less of change. Fitted at 8-12 years of age.

MiSight® 1 day clinical trial — Part 1

- 41% of the MiSight® group showed no meaningful progression in refractive error® after 3 years, compared with 4% in the control group¹
- Children as young as 8 can be successfully fit with soft, daily disposable soft contact lenses§1
- Children as young as 8 are able to handle their lenses confidently soon after initial fitting¹¹
- † Compared with a standard single-vision one-day lens over a three-year period.
- ‡ No clinically meaningful change in refractive error -0.25D or less from baseline
- § >95% of children were successfully fit with MiSight* 1 day or Proclear* 1 day.

 | Children new to contact lens wear aged 8-12, n= 130 @ 1 month after dispense.

MiSight® 1 day clinical trial — Part 2

- Children wearing MiSight® 1 day for 6 years progressed less than 1.00 D on average †3
- New and established MiSight[®] 1 day wearers have comparable rates of myopic progression and axial length growth³
- Older children[‡] adapted to spherical contact lenses achieved excellent visual acuity[§] when they switched to MiSight[®] 1 day^³

† Fitted at 8-12 years of age at initiation of treatment. ‡ Median age at switching 13.0 ± 1.5 years. § VA (LogMAR >6/6 (20/20)) at all visits from dispensing to 6-year visit.

MiSight® 1 day clinical trial — Part 3

• Phase 3 of the clinical trial will follow the children for one additional year to evaluate for post-treatment effect

For further details, please contact your local CooperVision sales representative or visit coopervision.com.

Indications for use: MiSight* 1 day (omafilcon A) soft (hydrophilic) contact lenses for daily wear are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 to -4.00 diopters (spherical equivalent) with ≤ 0.75 diopters of astigmatism. The lens is to be discarded after each removal.

References: 1. Chamberlain P, et al. A 3-year randomized clinical trial of MiSight lenses for myopia control. Optom Vis Sci. 2019;96:556–567. 2. CONSORT 2010 Explanation and Elaboration: Updated guidelines for reporting parallel group randomized trials BMJ. 2010;340:c869 doi: 10.1136/bmj.c869. 3. Chamberlain P, Arumugam B, Jones D et al. Myopia Progression in Children wearing Dual-Focus Contact Lenses: 6-year findings. Optom Vis Sci 2020;97(E-abstract): 200038. 4. Tideman J, et al. Association of axial length with risk of uncorrectable visual impairment for Europeans with myopia. JAMA Ophthalmol. 2016;134:1355-1363. 5. Woods, Jill et al. Ocular health of children wearing daily disposable contact lenses over a 6-year period. Contact Lens





MiSight 1 day:

Test group (MiSight® 1 day)

Control group (Proclear® 1 day)

Setting a clinical standard with the longest continuous soft contact lens study for myopia management^{1,2}



A 7-year clinical trial separated into three parts:1,3

Part 2 (Years 4-6)³ Part 1 (Years 1-3) Quantify the effectiveness of MiSight® 1 day Compare the rate of myopia progression Objective between children new to MiSight® 1 day§ and in slowing the rate of myopia progression those who had worn MiSight® 1 day for the compared to a single vision 1 day lens over a 3-year period* previous 3 years Randomized + double-masked All children wearing MiSight[®] 1 day • Ages 8-12 • Ages 11–15 • 108 children from Part 1 144 children continued into Part 2 Prospective Double-masked N/A Randomized N/A Multicenter (Singapore, Canada, England, Portugal) Participants:

Part 3 (Year 7)

70 children aged 8–12 years

74 children aged 8–12 years

Phase 3 of the clinical trial will follow the children for one additional year to evaluate for post-treatment effect

§ Median age at switching 13.0 \pm 1.5 years.

108 children aged 11–15 years

Indications for use: MiSight* 1 day (omafilcon A) soft (hydrophilic) contact lenses for daily wear are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 to -4.00 diopters (spherical equivalent) with \leq 0.75 diopters of astigmatism. The lens is to be discarded after each removal.

*Proclear® 1 day




MiSight® 1 day clinical study outcomes

Part 1 (Years 1-3)

Objective: Quantify the effectiveness of MiSight® 1 day in **slowing the rate of myopia progression** compared to a single vision 1 day lens over a 3-year period*

Result: 59% on average reduction in myopia progression with MiSight® 1 day¹

Changes in refractive error^{1,3}



Result: 52% on average reduction in axial elongation with MiSight® 1 day¹

Changes in axial length^{1,3}


• Increased axial length is associated with a higher likelihood of visual impairment⁴



Part 2 (Years 4-6)

Objective: Compare the rate of myopia progression between children new to MiSight® 1 day§ and those who had worn MiSight® 1 day for the previous 3 years

Result: New and established **MiSight® 1 day** wearers had comparable rates of myopic progression³



Result: New and established MiSight® 1 day wearers had comparable rates of axial length growth³

